Rexlemestrocel-L
AssetCell therapyAlso DREAM HF-1, MPCs, MSB-DR003, MPC-06-ID
Allogeneic mesenchymal precursor cell therapy delivered with hyaluronic acid
- Stage
- Phase 3
- Modality
- Cell therapy
- Target
- Inflammation
- Indications
- 3
- Trials
- 3
- Developers
- 1
Indications
3Chronic heart failure
Phase 3COMPLETEDNCT02032004clinicaltrials.gov7 Oct 2026
Chronic low back pain
Phase 3investorsmedia.mesoblast.com7 Oct 2026
Degenerative disc disease
Phase 3COMPLETEDNCT02412735clinicaltrials.gov7 Oct 2026
- Targets and what it contains2
- Owner and partners2
- Trials3
- Evidence for its targets2
- Competitors4
- Aging relevance3
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 4 sources